City
Epaper

Stopped manufacturing, supply of additional Covishield doses, disclosed all side effects: Serum Institute

By IANS | Updated: May 8, 2024 18:10 IST

New Delhi, May 8 As British-Swedish pharma giant AstraZeneca recalled its Covid-19 vaccine globally, Pune-based Serum Institute of ...

Open in App

New Delhi, May 8 As British-Swedish pharma giant AstraZeneca recalled its Covid-19 vaccine globally, Pune-based Serum Institute of India (SII) on Wednesday said it stopped the manufacturing and supply of additional doses of Covishield in December 2021.

AstraZeneca has voluntarily withdrawn the "marketing authorisation" of its Covid vaccine, sold as Covishield in India and Vaxzevria in Europe.

In a statement to IANS, an SII spokesperson said that with India achieving high vaccination rates in 2021 and 2022, coupled with the emergence of new mutant variant strains, the demand for previous vaccines diminished significantly.

"Consequently, since December 2021, we have stopped the manufacturing and supply of additional doses of Covishield," the spokesperson added.

The Serum Institute said that they fully understand the ongoing concerns and "it's crucial to emphasise our commitment to transparency and safety".

The company said that from the outset, "we have disclosed all rare to very rare side effects, including Thrombosis with Thrombocytopenia Syndrome, in the packaging insert in 2021".

Thrombotic Thrombocytopenic Syndrome (TTS) is a rare side effect that can cause people to have blood clots and a low blood platelet count, linked to at least 81 deaths in the UK as well as hundreds of serious injuries.

The SII stressed that despite the challenges faced during the global pandemic, the safety of the vaccine remains paramount.

"Regardless of whether it's AstraZeneca's Vaxzervria or our own Covishield, both vaccines have been instrumental in saving millions of lives worldwide.

"We commend the collaborative efforts of governments and ministries in facilitating a unified global response to the pandemic," added the Serum Institute.

Meanwhile, the British-Swedish multinational pharmaceutical is also being sued by more than 50 alleged victims and grieving relatives in a High Court case in the UK.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

TechnologyNifty, Bank Nifty hit record highs, Sensex up 0.67 pc

BusinessNifty, Bank Nifty hit record highs, Sensex up 0.67 pc

National 'Shabdotsav 2026' begins at Dhyan Chand stadium, Delhi CM inaugurates ceremony 

NationalDifficult to understand how this mindset develops: VHP as anti-national song played in Palghar

BusinessCash Ur Drive to Deploy 10 EV Charging Stations with Advertising Rights in Rishikesh

Health Realted Stories

HealthIndia rises from 123rd to 8th globally in WHO pharmacovigilance contributions: Nadda

HealthUma Bharti lashes out at MP govt over Indore water contamination tragedy

HealthPriyanka Chaturvedi seeks urgent govt attention on AI apps on X sexualising women

HealthAyushman Bharat, Universal immunisation programme boosting healthcare in India: Govt

HealthFAIFA urges government to roll back steep tax hike on tobacco products